Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

(2019) Maddalena Centanni et al.   CLINICAL PHARMACOKINETICS

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

(2019) Douglas B. Johnson et al.   Journal for ImmunoTherapy of Cancer

Factors associated with acute exacerbations of myasthenia gravis

(2019) Rohit Reddy Gummi et al.   MUSCLE & NERVE

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuromuscular complications of immune checkpoint inhibitor therapy

(2018) Noah A. Kolb et al.   MUSCLE & NERVE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myositis as an adverse event of immune checkpoint blockade for cancer therapy

(2018) Mohsin Shah et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review

(2018) Kun Huang et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors

(2018) Justin C. Kao et al.   Current Neurology and Neuroscience Reports

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

(2017) D. Makarious et al.   EUROPEAN JOURNAL OF CANCER

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma

(2017) Yu-Hsiu Chen et al.   MEDICINE

Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients

(2017) Bella H.V. Nguyen et al.   MELANOMA RESEARCH

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

(2017) Shigeaki Suzuki et al.   NEUROLOGY

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

(2017) Natalia L. Gonzalez et al.   NEUROMUSCULAR DISORDERS

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

(2017) James Larkin et al.   ONCOLOGIST

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Myasthenic crisis and polymyositis induced by one dose of nivolumab

(2016) Toshihiro Kimura et al.   CANCER SCIENCE

Adjuvant ipilimumab in stage III melanoma: New landscape, new questions

(2016) Alexander M.M. Eggermont   EUROPEAN JOURNAL OF CANCER

Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma

(2016) Teresa C. Longoria et al.   Expert Opinion on Drug Metabolism & Toxicology

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

(2016) Nico Melzer et al.   JOURNAL OF NEUROLOGY

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

(2015) Takushi Shirai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Geographical Distribution of Myasthenia Gravis in Northern Europe - Results from a Population-Based Study from Two Countries

(2015) Marion I. Boldingh et al.   NEUROEPIDEMIOLOGY

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

(2015) Jeffrey T. Guptill et al.   Neurotherapeutics

Glucocorticoids in myasthenia gravis - if, when, how, and how much?

(2014) S. Hoffmann et al.   ACTA NEUROLOGICA SCANDINAVICA

Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?

(2013) Emily Choi Decroos et al.   MUSCLE & NERVE

Comparison of IVIg and PLEX in patients with myasthenia gravis

(2011) D. Barth et al.   NEUROLOGY

Heart disease in myasthenia gravis

(2010) Håkon Hofstad et al.   ACTA NEUROLOGICA SCANDINAVICA

Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis

(2009) Shigeaki Suzuki   ARCHIVES OF NEUROLOGY

Lifetime course of myasthenia gravis

(2007) David Grob et al.   MUSCLE & NERVE